Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

multi-kinase inhibitor LNK01002

An orally bioavailable inhibitor of three as of yet undisclosed kinases, with potential antineoplastic activity. Upon oral administration, multi-kinase inhibitor LNK01002 inhibits the activity of the three as of yet undisclosed kinases. This may result in antitumor activity in tumor cells in which these kinases are upregulated or dysregulated.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	triple kinase inhibitor LNK01002
Code name:	LNK 01002 LNK-01002 LNK-1000318 LNK01002

multi-kinase inhibitor LNK01002

Search NCI's Drug Dictionary